Mostrando 4 resultados de: 4
Filtros aplicados
Área temáticas
Enfermedades(4)
Ginecología, obstetricia, pediatría, geriatría(3)
Farmacología y terapéutica(2)
Fisiología humana(1)
Origen
scopus(4)
A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia
ArticleAbstract: Context: Patients with classic congenital adrenal hyperplasia (CAH) often require supraphysiologic gPalabras claves:adrenal hypertrophy, ATR-101, Clinical trial, Congenital adrenal hyperplasia, nevanimibeAutores:Chang A.Y., El-Maouche D., Joyal E.G., Lin V.H., Merke D.P., Mohideen P., Plaunt M.R., Richard J. Auchus, Turcu A.F., Vogiatzi M.G., Weintraub L.Fuentes:scopusCorrection to: Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies (The Journal of Clinical Endocrinology and Metabolism (2021) 106:11 (e4666-e4679) DOI: 10.1210/clinem/dgab438)
OtherAbstract: Table 2 contained an error in the listed dose. For cohort B, the dose was incorrectly listed as 200Palabras claves:Autores:Barnes C.N., Huang M., Imel E.A., Madu I.J., Merke D.P., Moriarty D., Nakhle S., Newfield R.S., Richard J. Auchus, Sarafoglou K., Vogiatzi M.G.Fuentes:scopusCrinecerfont Lowers Elevated Hormone Markers in Adults with 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia
ArticleAbstract: Context: Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is charactePalabras claves:17-hydroxyprogesterone, 21-hydroxylase deficiency, Congenital adrenal hyperplasia, crinecerfont, NBI-74788Autores:Chan J.L., Davis S.M., Farber R.H., Fechner P.Y., Giri N., Imel E.A., Richard J. Auchus, Roberts E., Sarafoglou K., Sturgeon J., Vogiatzi M.G.Fuentes:scopusTildacerfont in Adults with Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies
ArticleAbstract: Context: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is typically treatePalabras claves:17-hydroxyprogesterone, adrenocorticotropic hormone, androstenedione, Congenital adrenal hyperplasia, CRF-receptor antagonist, tildacerfontAutores:Barnes C.N., Huang M., Imel E.A., Madu I.J., Merke D.P., Moriarty D., Nakhle S., Newfield R.S., Richard J. Auchus, Sarafoglou K., Vogiatzi M.G.Fuentes:scopus